In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

The healthcare company's pivot into a new set of technologies will have many implications for the stock.

A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly ...

(Reuters) -German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk ...

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy ...

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...

2024年3月15日，尽管Novo Nordisk（NYSE:NVO）的II期肥胖试验结果不尽如人意，TD Cowen仍维持其买入评级和155.00美元的目标价。该试验研究了公司的CB1阻断剂monlunabant，在16周时显示约6-7%的体重减轻。 这次更新未能达到预期的疗效和安全性，但未发现严重的神经精神不良事件。然而，接受monlunabant治疗的参与者出现轻度至中度神经精神副作用的情况 ...

Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of ...

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...